Focus On Transfusion Dependent Thalassemia Patients Who Are Inadequate Responders To Deferasirox 35mg Kgqd

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Focus On Transfusion Dependent Thalassemia Patients Who Are Inadequate Responders To Deferasirox 35mg Kgqd trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

All recent trials (1 shown)

WithdrawnPhase 2

NCT01948817

Deferasirox BID (Twice a Day) in Transfusion Dependent Thalassemia Patients With Inadequate Response to High Doses

This is an open label, single arm, and multicenter study. The study will include the following phases. A screening phase which lasts for 4 weeks to determine pa…

Location not specified0Started 2014-02

Treatment: Deferasirox